SEC Tracker
Get the app

Vivos Therapeutics VVOS

Vivos Therapeutics reports $21.23M net loss for 2025

Proxy statement

Form
DEF 14A
Filed
Importance
Routine
  1. Net loss of $21.23 million for the year ended Dec 31, 2025
  2. Annual meeting of stockholders scheduled for Dec 2, 2026
  3. Proposal to ratify Haynie & Company as auditor for 2026
  4. Proposal for reverse stock split at 1-for-20 to 1-for-40

Written from the DEF 14A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Vivos Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Positron POSC public float $22M, Jun 30, 2025
  2. United Health Products UEEC public float $25M, Jun 30, 2025
  3. Allurion Technologies ALUR public float $21M, Jun 30, 2025
  4. Neuroone Medical Technologies NMTC public float $26M, Mar 31, 2025, over 18 months old
  5. Precision Optics POCI public float $26M, Dec 31, 2025